Pharmaceuticals

European Commission Approves Menarini Group's ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

* Each year in Europe more than 550,000 patients are diagnosed with breast cancer, of whom 70% have estrogen receptor (ER)-positive disease¹; more than 147,000 breast cancer patients inEurope die annually from the disease² * ORSERDU is the first treatment specifically for patients with ER+, HE...

2023-09-20 23:27 3505

AffaMed Therapeutics Announces First Patient Treated in Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA® for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmologic, neurological and psychiat...

2023-09-20 09:00 4362

Everest Medicines Announces China Center for Drug Evaluation of NMPA Recommends Priority Review for Cefepime-Taniborbactam for the Treatment of Complicated Urinary Tract Infections, including Pyelonephritis

SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing, manufacturing, and commercializing transformative pharmaceutical products and vaccines inGreater China and other parts of Asia, announced today that the Center for Drug E...

2023-09-20 08:26 3171

Cerecin strengthens position in neurometabolism with addition to pipeline

* Cerecin completes in-licensing of an investigational radiolabelled tracer 18FBHB, CER-022, for development and usein positron emission tomography (PET) studies of ketone body metabolism * Company expands ketogenic platform following pilot data of CER-0001 in migraine and infantile spasms. ...

2023-09-19 19:39 3298

Canton Biologics Completes Over 300 Million Yuan Series C Financing, Led by SDIC Venture Capital

GUANGZHOU, China, Sept. 18, 2023 /PRNewswire/ -- On September 13th, Canton Biologics Co., Ltd. announced that it had recently completed a Series C financing round exceeding300 million yuan. This round of financing was led by SDIC Venture Capital, with participation from Guangdong Technology Finan...

2023-09-18 18:43 4045

Biosyngen received the Asia Pacific Cell & Gene Therapy Excellence Awards (APCGTEA) 2023

SINGAPORE, Sept. 18, 2023 /PRNewswire/ -- On September 14, 2023, Biosyngen Pte Ltd (hereinafter referred to as "Biosyngen") was the recipient of the prestigious "Most Promising Cell Therapy Pipeline in APAC" award at the 7th Annual Cell & Gene Therapy World Asia 2023, amidst a pool of internation...

2023-09-18 17:53 2915

New drug class prevents key ageing mechanism in organ transplants

ATHENS, Greece, Sept. 18, 2023 /PRNewswire/ -- A novel study has shown that Senolytics, a new class of drugs, have the potential to prevent the transfer of senescence, a key mechanism of ageing, in recipients of older donor organs.  The pioneering research, presented today at the European Societ...

2023-09-18 06:01 2884

YS Biopharma Granted Patent in the U.S. for Immunotherapy Targeting Chronic Hepatitis B Virus Infection

GAITHERSBURG, Md., Sept. 15, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...

2023-09-15 20:30 3265

Neoss® Group has launched a new wireless intraoral scanner, NeoScan™ 2000

ZURICH, Sept. 15, 2023 /PRNewswire/ -- Neoss Group, a leading innovator in dental implant solutions, is proud to announce the fast and easy-to-use wireless intraoral scanner, NeoScan™ 2000. This follows the success of last year's launch of the NeoScan™ 1000.

2023-09-15 16:00 2735

Green Leadership Award Presented to Chugai Pharma Taiwan at the Asia Responsible Enterprise Awards 2023

SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- The Asia Responsible Enterprise Awards (AREA) 2023 is pleased to honor 30 outstanding business leaders and enterprises for championing sustainable and responsible business practices. Presented by leading regional NGO Enterprise Asia, the AREA is the mo...

2023-09-15 11:37 2596

MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study

GENEVA, Sept. 15, 2023 /PRNewswire/ -- MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now half way towards a planned 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimu...

2023-09-15 08:00 3299

Foundry Mixer Healthcare, Indonesian Minister of Health Budi G. Sadikin: "Together We Leapfrog Indonesia's Healthcare Transformation"

Indonesian Minister of Health, Budi Gunadi Sadikin, emphasized that investing in the Health Technology and Biotechnology sector serves not only business prospects but also strengthens Indonesia's health resilience and adds value to healthcare. JAKARTA, Indonesia, Sept. 14, 2023 /PRNewswire/ -- F...

2023-09-14 17:47 2683

Innovative Collaboration: Buzzreach and Oncoshot Spearhead Clinical Trial Advancements in Japan

SINGAPORE, Sept. 14, 2023 /PRNewswire/ -- Buzzreach and Oncoshot, two prominent entities in the clinical trials domain, have announced an impactful collaboration to accelerate clinical trials inJapan. The former specialises in clinical trial site recruitment and retention and project managemen...

2023-09-14 10:00 4522

Exelixis and Insilico Medicine Enter into Exclusive Global License Agreement for ISM3091, a Potentially Best-in-Class USP1 Inhibitor

— ISM3091 is a highly selective, orally bioavailable small molecule inhibitor of USP1  identified through Insilico Medicine's artificial intelligence (AI) platform, with potent activity in BRCA-mutated tumor models — — In May 2023, the U.S. Food and Drug Administration (FDA) cleared Insilico's I...

2023-09-13 20:29 4280

Menarini Asia-Pacific Enters into an Exclusive Licensing Agreement with Astellas to Commercialize Smyraf® in Taiwan and select South-East Asian markets

SINGAPORE, Sept. 13, 2023 /PRNewswire/ -- Menarini Asia-Pacific has entered into a long-term exclusive licensing partnership with Astellas Pharma Inc. (Astellas) for the development, manufacturing and commercialization of the orally administered Janus kinase (JAK) inhibitor Smyraf® 50 mg and 100 ...

2023-09-13 10:30 4360

Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration

CASTRES, France and BASEL, Switzerland, Sept. 12, 2023 /PRNewswire/ --  Pierre Fabre Laboratories , the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. This first acquisition of...

2023-09-12 20:00 2726

IPMG Drives Health Transformation and Strengthens Indonesia's Economy Through Efforts to Accelerate Access to Innovative Medicines and Vaccines, also Partnerships

JAKARTA,  Indonesia, Sept. 11, 2023 /PRNewswire/ -- The research and development-based multinational pharmaceutical industry association, the International Pharmaceutical Manufacturers Group (IPMG) is always committed to supporting and encouraging advocacy and transformation of Government policie...

2023-09-11 18:52 3064

Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer

AMSTERDAM, Sept. 11, 2023 /PRNewswire/ -- Norgine, a leading European specialist pharmaceutical company dedicated to improving the lives of patients, is pleased to announce the appointment ofSaulo Martiniano as its new Chief Operating Officer (COO). Saulo joins Norgine with a wealth of experience...

2023-09-11 15:00 2197

Biosyngen received FDA approval for Phase I/II Clinical Trials for BRL03, targeting Lung Cancer, Gastric Cancer and other advanced Solid Tumors

SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- On September 9th, 2023, Biosyngen Pte Ltd (hereafter as "Biosyngen") announced that the U.S. FDA has cleared the Investigational New Drug (IND) application for Phase I/II clinical trial ofBRL03 for the treatment of lung cancer, gastric cancer and other ad...

2023-09-11 14:53 2299

Nobel Trust Family Joins BIOHK2023 - Unveiling Key Announcement

HONG KONG, Sept. 8, 2023 /PRNewswire/ -- BIOHK2023 garnered widespread acclaim featuring an exceptional lineup of speakers, including aNobel Laureate, world-renowned scientists who have won distinguished awards, and accomplished biotech C-level venture capitalists taking the stage on 13th to 16th...

2023-09-08 16:30 3292
1 ... 102103104105106107108 ... 184

Week's Top Stories